Curon Biopharma of Shanghai Completes $150 Million Initial Financing

Curon Biophama, a Shanghai immuno-oncology startup, announced a $150 million Series A financing. 6 Dimensions Capital incubated the company and participated in the fundraising, which was joined by Boyu Capital and Temasek. Curon already has several "promising" novel cancer I-O agents in its pipeline, according to the company. It plans to use the proceeds of the funding to advance its pipeline products into pre-clinical and clinical development, while it expands its portfolio, presumably through in-licensing. More details....

Share this with colleagues:

Original Article: Curon Biopharma of Shanghai Completes $150 Million Initial Financing

More From BioPortfolio on "Curon Biopharma of Shanghai Completes $150 Million Initial Financing"